drugset / Trial / NCT00378196
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
RandomizedParallel-groupSingle-blindTreatment
Summary
This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.
Timeline
- Start
- 2006-09
- Primary completion
- 2007-09
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.3 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |